Seladelpar free acid
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 333113

CAS#: 851528-79-5 (free acid)

Description: Seladelpar, also known as MBX-8025 and RWJ-800025, is a selective peroxisome proliferator-activated receptor (SPPAR) -δ receptor agonist. MBX-8025 may have potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis.


Chemical Structure

img
Seladelpar free acid
CAS# 851528-79-5 (free acid)

Theoretical Analysis

MedKoo Cat#: 333113
Name: Seladelpar free acid
CAS#: 851528-79-5 (free acid)
Chemical Formula: C21H23F3O5S
Exact Mass: 444.12
Molecular Weight: 444.465
Elemental Analysis: C, 56.75; H, 5.22; F, 12.82; O, 18.00; S, 7.21

Price and Availability

Size Price Availability Quantity
10mg USD 150 2 Weeks
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 2650 2 Weeks
1g USD 3850 2 Weeks
2g USD 6450 2 Weeks
Bulk inquiry

Related CAS #: 851528-79-5 (free acid)   928821-40-3 (lysine hydrate)   928821-41-4 (lysine)   Seladelpar sodium    

Synonym: Seladelpar free acid; MBX-8025; MBX 8025; MBX8025; RWJ-800025; RWJ 800025; RWJ800025;

IUPAC/Chemical Name: (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid

InChi Key: JWHYSEDOYMYMNM-QGZVFWFLSA-N

InChi Code: InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1

SMILES Code: O=C(O)COC1=CC=C(SC[C@H](OCC)COC2=CC=C(C(F)(F)F)C=C2)C=C1C

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Seladelpar (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. The drug completed a phase II trial for primary biliary cholangitis. "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus." A phase III trial in patients with PBC also found reduced pruritus and improved liver biochemistry, despite being terminated early. from https://en.wikipedia.org/wiki/Seladelpar

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 444.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vuppalanchi R, Kowdley KV. Editorial: The evolving paradigms and treatments for primary biliary cholangitis. Aliment Pharmacol Ther. 2024 Jan;59(2):280-281. doi: 10.1111/apt.17779. PMID: 38153286.


2: Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, Johnson JD, McWherter CA, Choi YJ. Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728. Epub ahead of print. PMID: 38117036.


3: Choi YJ, Johnson JD, Lee JJ, Song J, Matthews M, Hellerstein MK, McWherter CA. Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Epub ahead of print. PMID: 38014444.


4: Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dörffel Y, Yang K, Choi YJ, McWherter CA. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. PMID: 37904314.


5: Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan MI, Regev A, Hayashi PH, Lewis JH, Mehta R, Harrison SA, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, Miller V, Chalasani N, Sanyal AJ. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25. PMID: 37877759.


6: Kamata S, Honda A, Ishikawa R, Akahane M, Fujita A, Kaneko C, Miyawaki S, Habu Y, Shiiyama Y, Uchii K, Machida Y, Oyama T, Ishii I. Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor. Antioxidants (Basel). 2023 Jul 29;12(8):1523. doi: 10.3390/antiox12081523. PMID: 37627519; PMCID: PMC10451623.


7: Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. PMID: 37386786; PMCID: PMC10344437.


8: Levy C, Manns M, Hirschfield G. New Treatment Paradigms in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19. PMID: 36809835.


9: Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. J Transl Autoimmun. 2023 Jan 5;6:100188. doi: 10.1016/j.jtauto.2023.100188. PMID: 36684809; PMCID: PMC9850184.


10: Xu C, Yue R, Lv X, Wang S, Du M. Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis. Front Pharmacol. 2022 Oct 20;13:835991. doi: 10.3389/fphar.2022.835991. PMID: 36339545; PMCID: PMC9631940.


11: Wetten A, Jones DEJ, Dyson JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8. PMID: 36194037.


12: Bowlus CL, Levy C, Hirschfield GM. Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!". J Hepatol. 2022 Nov;77(5):1452-1453. doi: 10.1016/j.jhep.2022.07.024. Epub 2022 Aug 14. PMID: 35977610.


13: Vijayakumar A, Okesli-Armlovich A, Wang T, Olson I, Seung M, Kusam S, Hollenback D, Mahadevan S, Marchand B, Toteva M, Breckenridge DG, Trevaskis JL, Bates J. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatol Commun. 2022 Sep;6(9):2298-2309. doi: 10.1002/hep4.2011. Epub 2022 Jun 23. PMID: 35735253; PMCID: PMC9426400.


14: Kouno T, Liu X, Zhao H, Kisseleva T, Cable EE, Schnabl B. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem. 2022 Jul;298(7):102056. doi: 10.1016/j.jbc.2022.102056. Epub 2022 May 20. PMID: 35605662; PMCID: PMC9214809.


15: Mishra AK, Singh SP. Seladelpar in patients with primary biliary cholangitis: Need for a closer look! J Hepatol. 2022 Nov;77(5):1451. doi: 10.1016/j.jhep.2022.04.039. Epub 2022 May 17. PMID: 35594993.


16: Dhingra S, Mahadik JD, Tarabishy Y, May SB, Vierling JM. Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct;54(6):686-693. doi: 10.1016/j.pathol.2022.01.009. Epub 2022 May 5. PMID: 35525796.


17: Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. PMID: 35367282.


18: Kremer AE, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, Steinberg A, McWherter CA, Choi YJ. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int. 2022 Jan;42(1):112-123. doi: 10.1111/liv.15039. Epub 2021 Aug 26. PMID: 34403559.


19: ENHANCE: Safety and Efficacy of Seladelpar in Patients With Primary Biliary Cholangitis-A Phase 3, International, Randomized, Placebo-Controlled Study. Gastroenterol Hepatol (N Y). 2021 Feb;17(2 Suppl 3):5-6. PMID: 34135711; PMCID: PMC8191827.


20: Chu H, Jiang L, Gao B, Gautam N, Alamoudi JA, Lang S, Wang Y, Duan Y, Alnouti Y, Cable EE, Schnabl B. The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res. 2021 Jan;227:1-14. doi: 10.1016/j.trsl.2020.06.006. Epub 2020 Jun 15. PMID: 32553670; PMCID: PMC7719076.